Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

422 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
CanDIG: Federated network across Canada for multi-omic and health data discovery and analysis.
Dursi LJ, Bozoky Z, de Borja R, Li H, Bujold D, Lipski A, Rashid SF, Sethi A, Memon N, Naidoo D, Coral-Sasso F, Wong M, Quirion PO, Lu Z, Agarwal S, Pavlov Y, Ponomarev A, Husic M, Pace K, Palmer S, Grover SA, Hakgor S, Siu LL, Malkin D, Virtanen C, Pugh TJ, Jacques PÉ, Joly Y, Jones SJM, Bourque G, Brudno M. Dursi LJ, et al. Among authors: siu ll. Cell Genom. 2021 Nov 10;1(2):100033. doi: 10.1016/j.xgen.2021.100033. eCollection 2021 Nov 10. Cell Genom. 2021. PMID: 36778585 Free PMC article.
Current and new frontiers in hereditary cancer surveillance: Opportunities for liquid biopsy.
Farncombe KM, Wong D, Norman ML, Oldfield LE, Sobotka JA, Basik M, Bombard Y, Carile V, Dawson L, Foulkes WD, Malkin D, Karsan A, Parkin P, Penney LS, Pollett A, Schrader KA, Pugh TJ, Kim RH; CHARM consortium. Farncombe KM, et al. Am J Hum Genet. 2023 Oct 5;110(10):1616-1627. doi: 10.1016/j.ajhg.2023.08.014. Am J Hum Genet. 2023. PMID: 37802042 Free PMC article. Review.
"I just wanted more": Hereditary cancer syndromes patients' perspectives on the utility of circulating tumour DNA testing for cancer screening.
Adi-Wauran E, Clausen M, Shickh S, Gagliardi AR, Denburg A, Oldfield LE, Sam J, Reble E, Krishnapillai S, Regier DA, Baxter NN, Dawson L, Penney LS, Foulkes W, Basik M, Sun S, Schrader KA, Karsan A, Pollett A, Pugh TJ; CHARM consortium; Kim RH, Bombard Y. Adi-Wauran E, et al. Eur J Hum Genet. 2024 Feb;32(2):176-181. doi: 10.1038/s41431-023-01473-y. Epub 2023 Oct 11. Eur J Hum Genet. 2024. PMID: 37821757
Prospective manipulation of the gut microbiome with microbial ecosystem therapeutic 4 (MET4) in HPV-related locoregionally-advanced oropharyngeal cancer squamous cell carcinoma (LA-OPSCC) undergoing primary chemoradiation: ROMA2 study.
Oliva M, Heirali A, Watson G, Rooney AM, Cochrane K, Jennings S, Taylor R, Xu M, Hosni A, Hope A, Bratman SV, Chepeha D, Weinreb I, Perez-Ordonez B, Nin RM, Waldron J, Xu W, Hansen AR, Siu LL, Coburn B, Spreafico A. Oliva M, et al. Among authors: siu ll. Br J Cancer. 2024 May 7. doi: 10.1038/s41416-024-02701-y. Online ahead of print. Br J Cancer. 2024. PMID: 38714747
State-Of-The-Art Advancements on Cancer Vaccines and Biomarkers.
Strum S, Andersen MH, Svane IM, Siu LL, Weber JS. Strum S, et al. Among authors: siu ll. Am Soc Clin Oncol Educ Book. 2024 Jun;44(3):e438592. doi: 10.1200/EDBK_438592. Am Soc Clin Oncol Educ Book. 2024. PMID: 38669611 Free article. Review.
Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (KEYNOTE-412): a randomised, double-blind, phase 3 trial.
Machiels JP, Tao Y, Licitra L, Burtness B, Tahara M, Rischin D, Alves G, Lima IPF, Hughes BGM, Pointreau Y, Aksoy S, Laban S, Greil R, Burian M, Hetnał M, Delord JP, Mesía R, Taberna M, Waldron JN, Simon C, Grégoire V, Harrington KJ, Swaby RF, Zhang Y, Gumuscu B, Bidadi B, Siu LL; KEYNOTE-412 Investigators. Machiels JP, et al. Among authors: siu ll. Lancet Oncol. 2024 May;25(5):572-587. doi: 10.1016/S1470-2045(24)00100-1. Epub 2024 Mar 29. Lancet Oncol. 2024. PMID: 38561010 Clinical Trial.
Ezabenlimab (BI 754091), an anti-PD-1 antibody, in patients with advanced solid tumours.
Patel MR, Johnson M, Winer I, Arkenau HT, Cook N, Samouëlian V, Aljumaily R, Kitano S, Duffy C, Ge M, Elgadi M, Siu LL. Patel MR, et al. Among authors: siu ll. Cancer Immunol Immunother. 2024 Mar 30;73(5):89. doi: 10.1007/s00262-024-03654-0. Cancer Immunol Immunother. 2024. PMID: 38554156 Free PMC article. Clinical Trial.
Multimodal detection of molecular residual disease in high-risk locally advanced squamous cell carcinoma of the head and neck.
Sanz-Garcia E, Zou J, Avery L, Spreafico A, Waldron J, Goldstein D, Hansen A, Cho BCJ, de Almeida J, Hope A, Hosni A, Hahn E, Perez-Ordonez B, Zhao Z, Smith C, Zheng Y, Singaravelan N, Bratman SV, Siu LL. Sanz-Garcia E, et al. Among authors: siu ll. Cell Death Differ. 2024 Apr;31(4):460-468. doi: 10.1038/s41418-024-01272-y. Epub 2024 Feb 26. Cell Death Differ. 2024. PMID: 38409276 Free PMC article.
Early changes in tumor-naive cell-free methylomes and fragmentomes predict outcomes in pembrolizumab-treated solid tumors.
Stutheit-Zhao EY, Sanz-Garcia E, Liu ZA, Wong D, Marsh K, Abdul Razak AR, Spreafico A, Bedard PL, Hansen AR, Lheureux S, Torti D, Lam B, Yang SYC, Burgener J, Luo P, Zeng Y, Cheng N, Awadalla P, Bratman SV, Ohashi PS, Pugh TJ, Siu LL. Stutheit-Zhao EY, et al. Among authors: siu ll. Cancer Discov. 2024 Feb 23. doi: 10.1158/2159-8290.CD-23-1060. Online ahead of print. Cancer Discov. 2024. PMID: 38393391
Impact on costs and outcomes of multi-gene panel testing for advanced solid malignancies: a cost-consequence analysis using linked administrative data.
Hernando-Calvo A, Nguyen P, Bedard PL, Chan KKW, Saleh RR, Weymann D, Yu C, Amir E, Regier DA, Gyawali B, Kain D, Wilson B, Earle CC, Mittmann N, Abdul Razak AR, Isaranuwatchai W, Sabatini P, Spreafico A, Stockley TL, Pugh TJ, Williams C, Siu LL, Hanna TP. Hernando-Calvo A, et al. Among authors: siu ll. EClinicalMedicine. 2024 Feb 12;69:102443. doi: 10.1016/j.eclinm.2024.102443. eCollection 2024 Mar. EClinicalMedicine. 2024. PMID: 38380071 Free PMC article.
422 results